Zynerba plummets 51% after its CBD gel fails trial for rare disease (ZYNE)

Zynerba plummets 51% after its CBD gel fails trial for rare disease (ZYNE)
  • Zynerba, a small biotechnology company, plummeted 51% on Tuesday after its CBD gel failed a pivotal trial for a rare disorder called Fragile X syndrome.
  • The company said its experimen…
    Read More

Leave a Reply

Your email address will not be published. Required fields are marked *